Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
41.71
-0.34 (-0.81%)
Mar 6, 2026, 1:26 PM EST - Market open
Xenon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 7.5 | - | - | 9.43 | 18.44 | |
| Revenue Growth (YoY) | - | - | - | -48.83% | -42.68% | |
| Cost of Revenue | 300.94 | 210.39 | 167.51 | 105.77 | 75.46 | |
| Gross Profit | -293.44 | -210.39 | -167.51 | -96.33 | -57.03 | |
| Selling, General & Admin | 79.63 | 68.9 | 46.54 | 32.81 | 21.97 | |
| Operating Expenses | 79.63 | 68.9 | 46.54 | 32.81 | 21.97 | |
| Operating Income | -373.07 | -279.3 | -214.05 | -129.14 | -78.99 | |
| Interest & Investment Income | 26.83 | 41.94 | 27.62 | 8.71 | 0.47 | |
| Currency Exchange Gain (Loss) | 1.35 | -1.06 | 0.2 | -1.89 | 0.36 | |
| EBT Excluding Unusual Items | -344.89 | -238.42 | -186.24 | -122.32 | -78.17 | |
| Gain (Loss) on Sale of Investments | - | - | 3.55 | -2.93 | -0.72 | |
| Pretax Income | -344.89 | -238.42 | -182.69 | -125.26 | -78.89 | |
| Income Tax Expense | 1.02 | -4.09 | -0.29 | 0.12 | -0.01 | |
| Net Income | -345.91 | -234.33 | -182.39 | -125.37 | -78.88 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | -1.8 | |
| Net Income to Common | -345.91 | -234.33 | -182.39 | -125.37 | -77.09 | |
| Shares Outstanding (Basic) | 79 | 78 | 67 | 61 | 44 | |
| Shares Outstanding (Diluted) | 79 | 78 | 67 | 61 | 44 | |
| Shares Change (YoY) | 1.75% | 16.45% | 10.48% | 38.77% | 21.09% | |
| EPS (Basic) | -4.36 | -3.01 | -2.73 | -2.07 | -1.77 | |
| EPS (Diluted) | -4.36 | -3.01 | -2.73 | -2.07 | -1.77 | |
| Free Cash Flow | -279.92 | -184.46 | -156.73 | -103.92 | -71.55 | |
| Free Cash Flow Per Share | -3.53 | -2.37 | -2.34 | -1.72 | -1.64 | |
| Operating Margin | -4974.27% | - | - | -1368.91% | -428.45% | |
| Profit Margin | -4612.13% | - | - | -1328.95% | -418.11% | |
| Free Cash Flow Margin | -3732.23% | - | - | -1101.57% | -388.09% | |
| EBITDA | -370.53 | -276.74 | -211.99 | -127.74 | -78.09 | |
| D&A For EBITDA | 2.54 | 2.56 | 2.06 | 1.41 | 0.91 | |
| EBIT | -373.07 | -279.3 | -214.05 | -129.14 | -78.99 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.